S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.52 (-0.27%)
NVDA   817.98 (-3.39%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.84 (-0.06%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   149.63 (-2.16%)
CGC   7.96 (+1.66%)
DIS   111.75 (-0.60%)
AMC   3.20 (+9.59%)
PFE   25.79 (+1.58%)
PYPL   62.05 (-0.08%)
XOM   120.26 (+1.47%)
Free Trial

United Therapeutics (UTHR) Stock Forecast & Price Target

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free uthr Stock Alerts
$236.28
-0.65 (-0.27%)
(As of 11:49 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

United Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$292.67
23.86% Upside
High Forecast$330.00
Average Forecast$292.67
Low Forecast$215.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$292.67$294.40$297.88$290.27
Predicted Upside23.86% Upside30.81% Upside28.17% Upside20.31% Upside
Get United Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

UTHR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UTHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

United Therapeutics Stock vs. The Competition

TypeUnited TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside23.65% Upside980.16% Upside11.86% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$309.00 ➝ $325.00+37.15%
2/22/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$308.00+40.52%
2/22/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$300.00+36.87%
2/12/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeSell ➝ Neutral$213.00 ➝ $215.00+1.25%
2/5/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Ruiz
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOutperform
2/5/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$330.00+54.63%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight ➝ Overweight$318.00 ➝ $314.00+37.61%
11/2/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$290.00 ➝ $294.00+28.85%
8/3/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$256.00 ➝ $268.00+11.27%
4/21/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$300.00 ➝ $280.00+24.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:08 PM ET.

UTHR Price Target - Frequently Asked Questions

What is United Therapeutics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for United Therapeutics stock is Moderate Buy based on the current 1 hold rating and 9 buy ratings for UTHR. The average twelve-month price prediction for United Therapeutics is $292.67 with a high price target of $330.00 and a low price target of $215.00. Learn more on UTHR's analyst rating history.

Do Wall Street analysts like United Therapeutics more than its competitors?

Analysts like United Therapeutics more than other Medical companies. The consensus rating score for United Therapeutics is 2.90 while the average consensus rating score for medical companies is 2.68. Learn more on how UTHR compares to other companies.

Is United Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, United Therapeutics's stock had 1 upgrade by analysts.

Does United Therapeutics's stock price have much upside?

According to analysts, United Therapeutics's stock has a predicted upside of 30.17% based on their 12-month stock forecasts.

What analysts cover United Therapeutics?

United Therapeutics has been rated by HC Wainwright, Leerink Partnrs, SVB Leerink, The Goldman Sachs Group, Wedbush, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:UTHR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends